JNJ - Johnson & Johnson
| Previous Close | 141.98 |
| Open | 142.18 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's Range | 141.69 - 143.13 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 13,283,427 |
| Avg. Volume | 6,112,773 |
| Market Cap | 383.313B |
| Beta | 0.53 |
| PE Ratio (TTM) | 284.06 |
| EPS (TTM) | 0.50 |
| Earnings Date | Oct 16, 2018 |
| Forward Dividend & Yield | 3.60 (2.58%) |
| Ex-Dividend Date | 2018-08-27 |
| 1y Target Est | 143.79 |
- Barrons.com•yesterday
Boston Scientific, Edwards Lifesciences May Tempt J&J
Either device maker could be a rewarding acquisition for the old-line pharma and consumer-product company
- PR Newswire•yesterday
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression TITUSVILLE, N.J. , Sept. 21, 2018 /PRNewswire/ -- The ...
- Market Realist•yesterday
How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
- Market Realist•2 days ago
Is Abbott Laboratories Trading at a High Valuation in September?
On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.
Markit•2 days agoSee what the IHS Markit Score report has to say about Johnson & Johnson.
Johnson & Johnson NYSE:JNJ
- Market Realist•2 days ago
Abbott Laboratories’ 379th Consecutive Quarterly Dividend
On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.
- CNBC•2 days ago
'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus
CNBC's Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis. Cohen says that his small pharmaceutical company is beating big pharma when it comes to these treatments.
InvestorPlace•2 days ago7 Dow Jones Stocks Leading the Push to New Highs
The Dow Jones Industrial Average finally pushed above its January record high on Thursday, ending a year-long consolidation range that was spurred by worries over higher interest rates, Federal Reserve policy tightening and the fallout from President Trump’s trade war.
- MarketWatch•2 days ago
Here’s a clear case for owning dividend stocks instead of bonds
Hank Smith, co-chief investment officer of Haverford Trust, has laid out a clear case for dividend stocks over bonds. Pepsi’s stock had a dividend yield of 3.25% as of the close on Sept. 18, while 10-year U.S. Treasury paper yielded 3.05%.
Market Realist•2 days agoAnalysts Are Overwhelmingly Bullish on Abbott Laboratories
Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.
American City Business Journals•3 days agoLake Nona appears set to land big biotech facility
Before dirt even has been tossed, a future biotech manufacturing plant in Lake Nona’s 650-acre Medical City is dreaming up expansion plans. The 18-acre site — likely slated for Cranbury, N.J.-based global tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) — already is being considered for a planned development with manufacturing, office and warehouse space. Real estate sources said Amicus likely is the company behind Project Olympus.
Market Realist•3 days agoWhat Quest Diagnostics’ Valuation Trend Indicates
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.
- Market Realist•3 days ago
Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates
Merck & Co. reported a rise of 5% in its top line to ~$10.5 billion in the second quarter, including a 4% rise in operating revenue and a 1% favorable impact of foreign exchange. This revenue growth was driven by the strong sales of Keytruda, the Gardasil franchise, ProQuad/Varivax, RotaTeq, Pneumovax 23, Bridion, Noxafil, Simponi, Belsomra, Isentress, Januvia, Janumet, Atozet, Adempas, and a few other drugs from its pharmaceutical business.
- PR Newswire•3 days ago
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
Market Realist•3 days agoTaking Stock of Quest Diagnostics’ Recent Acquisitions
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.
Market Realist•3 days agoHow Quest Diagnostics Is Positioned in 2018
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
- Zacks•3 days ago
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
- Benzinga•4 days ago
The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 18.) Boston Scientific Corporation (NYSE: BSX ) Cara Therapeutics ...
- MarketWatch•4 days ago
Health care ETF surges toward record in a broad sector rally
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
- Reuters•5 days ago
Exclusive - India, U.S. closing in on package deal to remove trade irritants
Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said. Having skirmished for months over tit-for-tat tariffs on steel and some agricultural products, the two sides began talks in June that also cover India's concerns over U.S. steel tariffs and U.S. problems with Indian tariffs on imported IT equipment. U.S. President Donald Trump, who dislikes multilateral trade agreements, said earlier this month that India had approached the United States to "start doing a trade deal," without giving any details.
- InvestorPlace•5 days ago
Cronos Gets Bigger As It Partners With Ginkgo Bioworks
From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.
- Zacks•5 days ago
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
- Zacks•5 days ago
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
- Bloomberg•5 days ago
J&J Talc Supplier Takes No Chances on Another Big Jury Loss
Imerys SA, which supplies talc to Johnson & Johnson, isn’t taking chances as another jury weighs whether to sock the health-care giant with a punishing verdict. A unit of Imerys agreed to settle its part of a California woman’s lawsuit blaming both companies for causing her cancer with asbestos-tainted talc at the conclusion of a four-week state-court trial in Pasadena, just before the case was sent to jury for deliberations. In July, a St. Louis jury ordered J&J to pay $4.69 billion in damages to 22 women who blamed their ovarian cancer on exposure to asbestos in the company’s powders.
- Zacks•5 days ago
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
